🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against superbug strains of the pathogen, according to health experts.

An International Challenge

Gonorrhoea infections are increasing around the world, with data suggesting in excess of 82 million infections annually. Particularly high rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the context of rising global incidence, escalating drug resistance and the very limited therapeutic options at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Authorization

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval signifies a significant shift in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Data and Global Access

Based on results released by a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which involves two antibiotics. The research involved nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the ability to license and sell the drug in many low-income and middle-income countries.

Clinicians treating patients have shared hope. The availability of a easy-to-administer therapy of this kind is hailed as a "game-changer" for gonorrhoea control. This is considered essential to alleviate the strain of the illness for individuals and to prevent the spread of untreatable gonorrhoea around the world.